Start-Up News October 2007
MiCardia has a new twist on annuloplasty for mitral regurgitation; Biosifica Inc.'s disposable dressing delivers electrical stimulation to a wound bed to encourage healing. Mobius Therapeutics aims to bring control and convenience to glaucoma surgery with an easy to use mitomycin C kit.
You may also be interested in...
NeoChord wants to enable less invasive mitral valve repair with the NeoChord DS1000 is a tool for implanting artificial chordae tendineae made of suturing material while the heart is still beating.
Over the last few years, interventional heart valve technologies have been among the most popular segments of the cardiovascular device market with venture investors. This popularity has resulted in some VCs concluding that the space has become saturated. While the market may be getting tougher to enter for newcomers, the successful financing rounds recently closed by Evalve and Mitralign show that investors--including new device investors--remain bullish on companies that can demonstrate an effective percutaneous alternative to existing surgical procedures.
Drug therapy has dominated glaucoma management for decades, but novel device technologies are shifting the way this disease is managed, adding promising new options to the previously limited treatment continuum. For companies active in this field, along with an increasing number of VCs targeting ophthalmology, this shift marks the beginning of a tremendous new opportunity--one that will involve challenges and risks, but that also offers a huge payoff for those able to provide the right technology at the right time.